BD, a leading global medical technology company, has recently announced a strategic partnership with Bactiguard, a Swedish infection prevention company. The partnership aims to exclusively license Bactiguard’s innovative technology for Foley catheters on a global scale, with the exception of China.
Foley catheters are widely used in healthcare settings to drain urine from the bladder. However, they can also pose a risk of urinary tract infections (UTIs) due to the colonization of bacteria on the catheter surface. Bactiguard’s unique technology addresses this issue by incorporating a thin coating of noble metals, such as gold and silver, onto the catheter surface. These metals have antimicrobial properties that help prevent bacterial colonization and reduce the risk of UTIs.
By partnering exclusively with Bactiguard, BD aims to enhance its portfolio of infection prevention solutions and provide healthcare professionals with a more effective tool to combat UTIs. The collaboration will enable BD to leverage its global reach and extensive distribution network to make Bactiguard’s technology more accessible to healthcare facilities worldwide.
UTIs are a significant healthcare burden, causing discomfort and complications for patients while also increasing healthcare costs. According to the Centers for Disease Control and Prevention (CDC), UTIs account for nearly 40% of all healthcare-associated infections. By reducing the incidence of UTIs, the partnership between BD and Bactiguard has the potential to improve patient outcomes and reduce the economic burden on healthcare systems.
The exclusive licensing agreement covers all markets except China, where Bactiguard has an existing partnership with another company. This strategic decision allows both BD and Bactiguard to maximize their market potential while ensuring that their technologies reach as many patients as possible.
BD’s commitment to infection prevention is well-established, and this partnership further strengthens its position in the market. The company offers a wide range of products and solutions designed to minimize the risk of infections in various healthcare settings. By adding Bactiguard’s innovative technology to its portfolio, BD can provide healthcare professionals with a comprehensive suite of infection prevention tools.
In addition to Foley catheters, BD and Bactiguard are exploring opportunities to expand their collaboration to other medical devices. This could include urinary catheters, central venous catheters, and other products where infection prevention is crucial.
The partnership between BD and Bactiguard represents a significant step forward in the fight against healthcare-associated infections. By combining their expertise and resources, the two companies are poised to make a meaningful impact on patient care and safety. With the global licensing of Bactiguard’s technology for Foley catheters, healthcare professionals can look forward to a more effective and reliable solution for preventing UTIs.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/bd-to-become-exclusive-global-license-partner-excluding-china-for-bactiguard-coated-foley-catheters-biospace/
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...